2. Academic Validation
  3. Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor

Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor

  • Bioorg Med Chem Lett. 2011 Mar 1;21(5):1438-41. doi: 10.1016/j.bmcl.2011.01.016.
Liming Shao 1,  Michael C Hewitt,  Fengjiang Wang,  Scott C Malcolm,  Jianguo Ma,  John E Campbell,  Una C Campbell,  Sharon R Engel,  Nancy A Spicer,  Larry W Hardy,  Rudy Schreiber,  Kerry L Spear,  Mark A Varney
Affiliations

Affiliation

  • 1 Discovery and Early Clinical Research, Sunovion Pharmaceuticals Inc., Marlborough, MA 01752, USA. liming.shao@sunovion.com
PMID: 21310609 DOI: 10.1016/j.bmcl.2011.01.016
Abstract

The current work discloses a novel cyclohexylarylamine chemotype with potent inhibition of the serotonin, norepinephrine, and dopamine transporters and potential for treatment of major depressive disorder. Optimized compounds 1 (SERT, NET, DAT, IC(50)=169, 85, 21 nM) and 42 (SERT, NET, DAT IC(50)=34, 295, 90 nM) were highly brain penetrant, active in vivo in the mouse tail suspension test at 30 mpk po and were not general motor stimulants.

Figures
Products